Does the regional use of intensive chemotherapy impact the outcome of adults with AML?
Saved in:
Main Author: | Corentin Orvain |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | BMJ Oncology |
Online Access: | https://bmjoncology.bmj.com/content/3/1/e000480.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?
by: Hester F Lingsma, et al.
Published: (2024-07-01) -
Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML
by: Naveed Ali, et al.
Published: (2025-02-01) -
G-CSF-Associated Bone Marrow Necrosis in AML after Induction Chemotherapy
by: Ikenna Osuorji, et al.
Published: (2012-01-01) -
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01) -
Polymorphisms in immunosuppression-related genes are associated with AML
by: Mingying Li, et al.
Published: (2025-02-01)